In cancer biology, it remains still open question concerning the oncogenic versus oncosuppressor behavior of metabolic genes, which includes those encoding mitochondrial complex I (CI) subunits. The prognostic value of nuclear genome mRNAs expression of CI subunits is to be evaluated in the tumor patients. We used the Kaplan Meier plotter database, the cBio Cancer Genomics Portal, and the Oncomine in which gene expression data and survival information were from thousands of tumor patients to assess the relevance of nuclear genome mRNAs level of CI subunits to patients' survival, as well as their alterations in gene and expression level in tumors. We presented that the relative expression level of overwhelming majority of the nuclear genes of CI subunits with survival significance (overall survival, relapse free survival, progression free survival, distant metastasis free survival, post progression survival, and first progression), had consistent effects for patients in each type of four tumors separately, including breast cancer, ovarian cancer, lung cancer, and gastric cancer. However, in gene level, frequent cumulative or individual alteration of these genes could not significantly affect patients' survival and the overexpression of the individual gene was not ubiquitous in tumors versus normal tissues. Given that reprogrammed energy metabolism was viewed as an emerging hallmark of tumor, thus tumor patients' survival might potentially to be evaluated by certain threshold for overall expression of CI subunits. Comprehensive understanding of the nuclear genome encoded CI subunits may have guiding significance for the diagnosis and prognosis in tumor patients.
According to the United States Cancer Statistics, as the second leading cause of death in the United States, cancer is expected to be the leading cause of death in the next few years [1] .
With high heterogeneity and complexity, despite advances in basic and clinical research, prognosis of malignant tumors remains discouraging due to the high postoperative recurrence rate and metastasis [2] . Therefore, the mechanism investigation for tumor incidence and progression, as well as tumor biomarkers identification are imperative and will help Abbreviations: NADH -Nicotinamide Adenine Dinucleotide Hydrogen; OXPHOS -Oxidative Phosphorylation; OS -Overall Survival; ROS -Reactive Oxygen Species; CI -Mitochondrial Complex I; mtDNA: mitochondrial DNA; nDNA -nuclear DNA to provide better prognostic prediction and individualized treatments for patients.
As was indicated in an analysis of mitochondrial DNA (mtDNA) mutations in the literatures scanned in Medline from 1998 to 2011, in 921 tumor cases where the entire mitochondrial genome had been sequenced, about 56% of all tumors contained at least one mutation, with 28% being in mitochondrial complex I (CI) and 35% in the Dloop [3] . Lu and colleagues reported similar results of mutations in mtDNA encoding CI subunits in a wide range of cancers [4] .
Albeit frequent mtDNA mutations being documented in cancer, [5] it is still elusive as to what a role they play in tumorigenesis, and how mitochondrial function can be affected by a specific mtDNA mutation type. Notably, none of the known pathogenic point mutations causing primary mitochondrial disease is demonstrably associated with tumor [6] . Only recently the concept of heteroplasmy and threshold effect has been introduced to investigate the mtDNA mutations' functional consequences during cancer progression [7, 8] .
Pelicano et al hold the view that mtDNA mutations result in downregulation of oxidative phosphorylation (OXPHOS) function, and thus promote tumor survival [9] . As the first and crucial component of mitochondrial respiratory chain, human CI comprises forty nine subunits. Forty two of them are encoded by the nuclear genome and assembled within both the hydrophilic and the hydrophobic arms [10] . While the remaining seven are encoded by mtDNA and constitute the hydrophobic arm, and together with the other seven nuclear gene-encoded ones, they constitute the evolutionarily conserved "core subunits" of CI, which are involved in the electron transfer and proton pumping. Whereas the rest "accessory" subunits may participate in stabilizing CI, regulating the enzymatic activity, preventing the generation of reactive oxygen species (ROS) or protecting the CI from oxidative damage [11, 12] .
Unlike the mtDNA, being affected by their distinct structure, replication and hereditary mode, as well as the hazardous environment, nuclear DNA (nDNA) encoding the mitochondria components are more stable. And far few studies had specially focused on mitochondria nDNA in tumor prognosis.
In the current study, for the first time we investigated the prognostic value of individual nuclear genes encoding CI subunits ('all genes' for short where appears following the passage), especially focusing on the seven core subunits genes ('core genes' for short where appears following the passage) as the representative, in different four types of tumor patients, using Kaplan Meier plotter (KM plotter) database. Then the gene-level and expression-level alterations of the 'all genes' and 'core genes' were explored through the cBio Cancer Genomics Portal and Oncomine. Furthermore, the relationship among their survival significances, alterations in gene and expression levels and the tumor reprogrammed energy metabolism was discussed.
Materials and methods
The Kaplan Meier plotter. The Kaplan Meier plotter (http:// kmplot.com/analysis/) was capable to assess the effect of 54675/22277 genes on survival using 10188 cancer samples, which included 4142 breast, 1648 ovarian, 2437 lung and 1065 gastric cancer patients with a mean follow-up of 69/40/49/33 months. The background database was established using gene expression data and patients survival information from the Cancer Biomedical Informatics Grid (caBIG, http://cabig. cancer.gov/), Gene expression Omnibus (GeO, http://www. ncbi.nlm.nih.gov/geo/), Cancer Genome Atlas (tCGA, http:// cancergenome.nih.gov), and the european genome-phenome archive (eGA, https://www.ebi.ac.uk/ega/), which was handled by a MySQL server and integrates gene expression and clinical data simultaneously [13] [14] [15] [16] .
In order to analyze the prognostic value of a particular gene, the cohorts were divided into two groups according to the median (or upper/lower quartile) expression of the gene. The two groups could be compared in terms of overall survival (OS), and relapse free survival (RFS), and so on [14] .
Briefly, the forty-two 'all genes' (NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, ND-UFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, NDUFB1, NDUFB10, NDUFB11, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFv1, NDUFv2, and NDUFv3) were individually entered into the database (http://kmplot.com/analysis/) respectively to obtain KaplanMeier survival plots in which the number-at-risk was indicated below the main plot. Hazard ratio (and 95 % confidence intervals) and log rank P value were calculated and displayed on the webpage.
The cBio Cancer Genomics Portal. The cBio Cancer Genomics Portal (http://cbioportal.org), developed at Memorial Sloan-Kettering Cancer Center (MSKCC), was specifically designed to address the unique data integration issues posed by large-scale cancer genomics projects, including the Cancer Genome Atlas (tCGA) and the International Cancer Genome Consortium (ICGC) [17] . It provided a web resource for exploring, visualizing, and analyzing multidimensional cancer genomics data, and presents us with graphical summaries of gene-level data from multiple platforms, network visualization and analysis, survival analysis, patient-centric queries, and software programmatic access.
We queried cross-cancer alteration summary for multigene cumulative alteration as well as individual gene changes in 105 cancer studies through the cBio Cancer Genomics Portal (www.cbioportal.org) to investigate the gene-level alterations of CI subunits in cancers.
Oncomine analysis. Oncomine, a cancer microarray database and web-based data-mining platform aimed at facilitating discovery from genome-wide expression analyses, in which differential expression analyses comparing most major types of cancer with respective normal tissues as well as a variety of cancer subtypes and clinical-based and pathology-based analyses were available for exploration [18] .
The individual gene of 'all genes' expression level was analyzed using Oncomine. We compared mRNA levels of cancer vs. normal patient datasets. We selected 1.5 fold change, P value=0.05, and top 10% gene rank as thresholds.
Results
Significant and consistent prognostic value of individual nuclear genes encoding CI core subunits in different cancer patients' survival. The CI was divided into six sub-complexes, and their 49 subunits were grouped to comprise their corresponding parts. The characteristics of the seven core subunits encoded by nDNA were shown in (S-table1 and S-table2) [9] .
Among all the 49 Mitochondrial CI subunits' genes, only the 7 mitochondrial genes were not found in the Kaplan Meier plotter (http://kmplot.com/), probably due to the lack of mtDNA data compared to the nDNA.
We first examined the OS of the seven 'core genes' mRNA expression in www.kmplot.com, for breast cancer, ovarian cancer, lung cancer and gastric cancer respectively. Survival curves were plotted for all patients (Figures 1-3) . The desired Affymetrix ID, Cases Number, Hazard Ratio (HR; and 95% confidence intervals) and Log Rank P were summarized in table1.
For breast cancer, high expression of the 'core genes' mRNA except for NDUFS3 and NDUFv2 was found to be correlated to worse OS in all breast cancer patients followed for 25 years ( Figure 1A , 1B, Figure 2A , 2B, 2C). While high level of NDUFv2 mRNA was found to be in relation with better OS, and NDUFS3 expression level had no significant OS for all breast cancer patients ( Figure 1C; 3A) . Integrated with the other 'all genes' in S-table4, it could be indicated that 24 out of the 42 'all genes' had worse, and 2 better OS for all breast cancer patients (Figure 3e) . Moreover, most of the "core genes" had worse OS in luminal B breast cancer patients (S-table3.1). And, for pathology grade I and/or II patients, majority of the "core genes" predicted worse OS (S-table3.2).
For ovarian cancer, high expression of NDUFS3, NDUFS7, NDUFS8 and NDUFv1 mRNA were found to be correlated to better OS in all ovarian cancer patients ( Figure 1C ; Figure  2A -C) However, NDUFS1 and NDUFS2 had the opposite effect. The Figure 3B showed that NDUFv2 expression had no significant OS for all ovarian cancer patients. together with the other 'all genes' in S-table4, it could be found that 15 out of the 42 'all genes' had worse, and 6 better OS for ovarian cancer patients (Figure 3e ). Additionally, for the pathology grade I and/or II ovarian cancer patients, most of the "core genes" had significant prognostic values, better or worse (S-table3.3). For serous ovarian cancer patients, almost all the "core genes" expression level could predicted better OS (S-table3.4). For lung cancer, the curves showed that high level of the seven 'core genes' apart from NDUFS1, contributed to worse OS in all lung patients ( Figures 1B, 1C , 2A-C, 3C). Although NDUFS1 expression above or below the median separated the patients into two groups, the Log Rank P value, however, was 0.069. Integrated with the other 'all genes' in S-table4, it could be indicated that 29 out of the 42 'all genes' had worse, and 2 better OS for lung cancer patients (Figure 3e ). Additionally, it could be indicated that, except for NDUFS1 predicting better OS, the other members of the "core genes" could predict worse OS, especially for adenocarcinoma or clinical stage I and II patients, which was in accordance with the NDUFS1 good and others worse for all patients (S-table3.5 and S-table3.6). While, whether the patients had smoking history or not, female or male, the "core genes" exhibited similar results as for all patients (S-table3.7 and S-table3.8).
What was more meaningful was that, for gastric tumor, the high expression of seven 'core genes' , apart from NDUFv1 with worse OS, had identically significant better OS in all gastric cancer patients ( Figure 1 , 2A-C; 3D). together with the other 'all genes' in S-table4, we amazingly found that 33 out of the 42 'all genes' had better OS for gastric cancer patients, none with worse OS (Figure 3e ). Furthermore, for well differentiated or clinical stage III and Iv patients, the "core genes" could predict better OS, except for NDUFv1 predicting worse OS, which was in accordance with the NDUFv1 worse and others good for all patients (S-table3.9, S-table3.10). While, whether the patients were intestinal type or diffuse type according to Lauren Classification, female or male, the "core genes" exhibited similar results as for all patients (S-table3.11, S-table3.12).
Additionally, we further queried the 'core genes' for other prognostic indicators in the four tumors, including relapse free survival (RFS), post progression survival (PPS) and distant metastasis survival (DMFS) for breast cancer; progression free survival (PFS), and PPS for ovarian cancer; first progression (FP) and PPS for lung cancer; FP for gastric cancer. Survival curves are plotted for all patients (S- Figure 2 -5). The desired Affymetrix ID, Cases Number, Hazard Ratio (HR; and 95% confidence intervals) and Log Rank P were summarized in S-table5. For breast cancer, as was shown in S- Figure 1 , apart from the genes with no prognostic significance (data not shown) and two (NDUFS8 and NDUFv2) with the opposite prognostic effect, the high expression of all the individual "core genes" was correlated with patients' worse survival, in accordance with the effect of them in the OS. For ovarian cancer, as was indicated in S- Figure 2 , the majority of the 'core genes' high expression had a good prognostic effect for all patients, only with NDUFS1 the opposite effect on FP. For both lung and gastric cancers, apart from the genes with no prognostic significance (not shown), high expression of the 'core genes' had identical prognostic significance to the OS respectively, as was shown in S- Figure 3 Briefly, for overwhelming majority of the 'all genes' with significant OS of the CI, relative expression level of the individual gene had consistent prognostic effect for patients in each of the four tumor separately (Figure 3e ).
While from another perspective, it could be demonstrated that for the individual gene, its influence on the four type of different tumor patients' survival were inconsistent, as was indicated in Figure 1 (A, D, G, J) for NDUFS1, Figure 1 Frequent cumulative alterations of the 'all genes' in various cancers while limited influence in patients' survival. Given that the expression level of individual 'all genes' of the CI had significant and identical influence on patients' survival, then we were interested in investigating the genes' alterations between normal and cancer patients in gene and expression-levels.
From the cross-cancer alteration summary for the 'all genes' in 105 studies including various tumors ( Figure 4A , 4B), it could be found that 86 of all the studies exhibited gene changes, among which almost half of them manifested that more than 30% of cancer patients burdened alterations of the genes in each of the study. Some individual studies even found that more than 80% patients held abnormal genes. Then we tested the 'core genes' in the same 105 studies. From the cross-cancer alteration summary ( Figure 4C , 4D), we found that 26 of the 79 studies showing genetic changes exhibited more than 15% of patients bearing gene alterations in each study.
Genetic alterations included four types, mutation, deletion, amplification, and multiple alteration, of which the amplification was prominent ( Figure 4A, 4C) . Additionally, the similar phenomenon occurred in the nuclear genes of the five CI subcomplexes respectively (http://cbioportal.org).
However, an interesting phenomenon was that, albeit significantly and widely amplification of the 'all genes' and 'core genes' in various tumors, only 5 out of the 86 studies for 'all genes' and 4 out of the 79 studies for 'core genes' exhibited that the cumulative alteration of genes had significant influence on the OS or disease free survival (DFS) of the patients, positive or negative (S- Figure 5A -I).
Furthermore, the alterations of individual gene occurred in only 0-15% of patients in each of the 105 studies, most of which less than 5%, and rarely was seen their significant influence on patients' survival (http://cbioportal.org).
In conclusion, cumulative or individual alteration of the 'all genes' in gene level could not significantly affect patients survival.
Overexpression of the individual CI subunits' gene was not ubiquitous in tumors versus normal tissues. From the perspective of molecular genetics, amplification is one of many ways in which a gene can be overexpressed [19] .
Therefore, we extracted the summary data on transcript expression for the 'core genes' from the database Oncomine for different tumors, focusing on clinical specimens of cancer vs. normal patient datasets.
As was shown in Figure 5 , for each of the seven 'core genes' , overwhelming majority of the datasets eligible for the screening condition did not show any expression changes. Although limited, the number of overexpression datasets was more than the downregulation number for most genes. Similar results were demonstrated in the other individual gene of the 'all genes' (S-table6). For gastric and lung tumors, the 'core genes' expression levels were in approximately accordant with their prognostic effects. While for breast and ovarian cancers, some paradoxical phenomena occurred between the 'core genes' mRNA levels and their prognostic effects, probably due to some unknown mechanisms, which remained to be elucidated.
Thus we could concluded that it was not ubiquitous for the overexpression of the individual CI subunits' gene in tumors versus normal tissues.
Discussion
As an emerging hallmark of tumor, [20] reprogrammed energy metabolism can be caused by aberration of oncogene and tumor suppressor genes, [21] as well as can result from mutations in mtDNA [4] . Consequently OXPHOS function is disturbed, and ROS production elevated, then DNA damaged and oncogenic signaling pathways activated, which can further promote cancer cell metabolic reprogramming, hypoxia adaptation, uncontrolled growth and metastasis [3] . A vicious circle forms.
eighty years ago, Warburg observed that tumor cells produced excess lactate in the presence of oxygen due to mitochondrial dysfunction, [22] which was known as the 'Warburg effect' or aerobic glycolysis. However, it is now clear that many tumor cells are capable of performing oxidative phosphorylation, and mitochondrial function is essential for cancer cell viability [23] . The 'reverse Warburg effect' presents that ROS produced from cancer cells can cause adjacent stromal fibroblasts cells mitophagy through inactivating caveolin-1, then lactate production increases in these stromal cells, which can further fuel cancer cell oxidative metabolism [24] .
During tumor progression, cancer cells suffer various survival pressures, including the insufficient in nutrient and O 2 supplying, and the survivors must undergo processes of metabolic reprogramming and hypoxic adaptation [25] . In cancer biology, a still open question concerns whether metabolic genes including those encoding CI subunits play the oncogenic or oncosuppressor role [26] .
As the first and crucial component of mitochondrial respiratory chain, CI plays a crucial role in several biochemical processes, such as the cellular redox status (NAD + /NADH ratio and ROS levels) maintenance, mitochondrial membrane potential generation and finally for AtP production [27].
Moreover, for highly proliferating tumor cells, mitochondrial respiratory chain function is indispensable for the synthesis of the pyrimidines that cells used to divide [28] . Thus, disturbance in CI stability or activity not only undermine mitochondrial functions but also destruct cellular homeostasis, inducing widespread consequences such as activation of autophagy or apoptosis [29] .
It seems that complete disassembly of CI caused by nucleotide alterations is disadvantageous for the tumor, i.e. leading to HIF1α destabilization, with adverse effect on hypoxic adaptation [30] . Conversely, those less destructive somatic mutations, such as missense variants, may be maintained in tumor tissue, as they may instead positively promote HIF1α function and contribute to metabolic adaptation through decreasing, but not abrogating, CI function [30] .
Oxygenation is actually not necessarily static in tumor cells but instead waves regionally and temporally, ranging from normoxia to hypoxia, due to the instability and chaotic organization of the tumor-associated neovasculature, [31] which exposes the mitochondria in variable oxygen conditions. Thus together with the "reverse Warburg effect", in which two subpopulations of cancer cells function symbiotically to fuel tumor growth, we can conclude that the OXPHOS may functions unstably in different tumors or in different stages or regions of one tumor. Additionally, it is well demonstrated that ROS plays a dose-dependent role in promoting cancer cells surviving or dying [32] . From the above, it is not difficult to understand the result that the relative expression level of the CI 'all genes' had reverse prognosis effect in different cancers, although the exact mechanisms are still to be elucidated. Due to tumor heterogeneity, the CI genes function might also vary, or even antipodal in the different subtypes or different stages of the same type of tumor. Thus precision medicine and individualized treatment were to be taken into account in their future clinical application.
Although the cumulative alterations of 'all genes' accounted for a large proportion in the thousands of patients populations, however, once specific to each person, maybe there were only partial or even individual gene alterations. Additionally, due to the diverse alterations, including mutation, deletion, amplification, and multiple alteration, it was hard to evaluate how the single amplification affect patients' survival.
Being programmed by proliferation-inducing oncogenes, reprogrammed energy metabolism was viewed as an emerging hallmark of tumor [20] . Thus it was proposed that function of the multi-subunits comprising CI might not be affected by only partial or individual subunits alterations, but the 'all genes' might be up or down regulated simultaneously in response to the respiratory chain activity. And the overall expression level and their threshold for survival evaluation of CI subunits for tumor patients were expected for investigation in large scale of population through the same platform by the uniform standards.
Although data from the three independent platforms were not comparative, while, all the three platforms contained as much as thousands of patients' information, to some extent, at least, they were illustrative enough to suggest the conclusions. And further investigation with more perfect design was still needed.
In this study, we presented that for overwhelming majority of the 'all genes' of the CI, relative expression level of the individual gene had consistent prognostic effect for patients in breast, ovarian, lung, and gastric tumors separately. However frequent cumulative or individual alterations of the 'all genes' in gene level could not significantly affect patients' survival. And the overexpression of the individual CI subunits' gene was not ubiquitous in tumors versus normal tissues. Given that reprogrammed energy metabolism was viewed as an emerging hallmark of tumor, thus tumor patients' survival might potentially to be evaluated by the overall expression level of CI subunits.
Comprehensive understanding of the nuclear genome encoded CI subunits may have guiding significance for the diagnosis and prognosis in tumor patients. Based on our study, the discovery of the systematic molecular mechanisms that how CI subunits reflect or lead to different outcomes of tumor patients can pave a way for more effective tumor diagnosis and treatment. 
